Remikiren Information & Remikiren Links at HealthHaven.com

Remikiren
Systematic (IUPAC) name
	(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide
Identifiers
CAS number	126222-34-2
ATC code	C09XA01
PubChem	5462340
DrugBank	APRD00163
Chemical data
Formula	C33H50N4O6S
Mol. mass	630.839 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	83%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	? ;

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.^[1]

[edit] References

^ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica 26 (3): 243–54. PMID 8730917.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.